Properly designed clinical trials with nerve conduction studies, quantitative sensory testing, and symptom assessments would evaluate BPC-157's potential for peripheral nerve disorders
Various in vitro and in vivo models have already been adopted to assess the toxicity of NPs, including cell lines, 3D cell culture, zebrafish, rodents, and others (Saifi et al., 2018
Hattiangady B, Rao MS, Shetty AK
10.1136/gutjnl-2016-312574 Summary Keywords proton pump inhibitors, digestive diseases, microbiota, intestinal flora, Clostridium difficile , inflammatory bowel disease, short-chain fatty acids Citation Tian L, Huang C, Fu W, Gao L, Mi N, Bai M, Ma H, Zhang C, Lu Y, Zhao J, Zhang X, Jiang N, Lin Y, Yue P, Yuan J and Meng W (2023) Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota